心房颤动缺血性卒中患者服用秋水仙碱预防复发性卒中的效果:随机双盲安慰剂对照试验》。

IF 1.4 Q4 PHARMACOLOGY & PHARMACY
Zahra Molaeimanesh, Davood Kashipazha, Davood Shalilahmadi, Gholamreza Shamsaei, Shooka Mohammadi
{"title":"心房颤动缺血性卒中患者服用秋水仙碱预防复发性卒中的效果:随机双盲安慰剂对照试验》。","authors":"Zahra Molaeimanesh, Davood Kashipazha, Davood Shalilahmadi, Gholamreza Shamsaei, Shooka Mohammadi","doi":"10.2174/0115748871325292240904060109","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>It has been proposed that colchicine may have the potential to prevent cardiovascular and cerebrovascular dysfunctions.</p><p><strong>Objective: </strong>This study evaluated the impact of colchicine on preventing recurrent stroke in patients with both ischemic stroke (IS) and atrial fibrillation (AF).</p><p><strong>Methods: </strong>A randomized, double-blinded, placebo-controlled trial was conducted at Golestan Hospital (Ahvaz, Iran) over one year, involving IS patients with AF. Demographic and clinical data were collected from the participants, who were then assigned to either the intervention or placebo groups. The experimental group was administered colchicine at a dosage of 0.05 mg twice daily for one year, while the control group received a placebo at a comparable dosage over the same timeframe.</p><p><strong>Results: </strong>In one year, 108 patients completed the study. There were 55 patients in the intervention group and 53 patients in the placebo group. During the second trimester of the trial, three patients in the colchicine group and 10 patients in the placebo group experienced recurrent strokes. Gastrointestinal issues were the most commonly reported complications (33 cases), followed by myalgia (8 patients). There were significant differences in the frequency of recurrent stroke and serum levels of C-reactive protein (CRP) between the colchicine and placebo groups (P < 0.05) after intervention.</p><p><strong>Conclusion: </strong>In this study, colchicine was effective in reducing recurrent stroke and CRP levels in IS patients with AF compared to the control group. Further randomized controlled trials with larger sample sizes and extended durations are recommended to validate the results of this trial.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Colchicine for Prevention of Recurrent Stroke in Ischemic Stroke Patients with Atrial Fibrillation: A Randomized Double-blinded Placebo-- controlled Trial.\",\"authors\":\"Zahra Molaeimanesh, Davood Kashipazha, Davood Shalilahmadi, Gholamreza Shamsaei, Shooka Mohammadi\",\"doi\":\"10.2174/0115748871325292240904060109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>It has been proposed that colchicine may have the potential to prevent cardiovascular and cerebrovascular dysfunctions.</p><p><strong>Objective: </strong>This study evaluated the impact of colchicine on preventing recurrent stroke in patients with both ischemic stroke (IS) and atrial fibrillation (AF).</p><p><strong>Methods: </strong>A randomized, double-blinded, placebo-controlled trial was conducted at Golestan Hospital (Ahvaz, Iran) over one year, involving IS patients with AF. Demographic and clinical data were collected from the participants, who were then assigned to either the intervention or placebo groups. The experimental group was administered colchicine at a dosage of 0.05 mg twice daily for one year, while the control group received a placebo at a comparable dosage over the same timeframe.</p><p><strong>Results: </strong>In one year, 108 patients completed the study. There were 55 patients in the intervention group and 53 patients in the placebo group. During the second trimester of the trial, three patients in the colchicine group and 10 patients in the placebo group experienced recurrent strokes. Gastrointestinal issues were the most commonly reported complications (33 cases), followed by myalgia (8 patients). There were significant differences in the frequency of recurrent stroke and serum levels of C-reactive protein (CRP) between the colchicine and placebo groups (P < 0.05) after intervention.</p><p><strong>Conclusion: </strong>In this study, colchicine was effective in reducing recurrent stroke and CRP levels in IS patients with AF compared to the control group. Further randomized controlled trials with larger sample sizes and extended durations are recommended to validate the results of this trial.</p>\",\"PeriodicalId\":21174,\"journal\":{\"name\":\"Reviews on recent clinical trials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reviews on recent clinical trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115748871325292240904060109\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews on recent clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748871325292240904060109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:有人认为秋水仙碱可能具有预防心脑血管功能障碍的潜力:有人认为秋水仙碱可能具有预防心脑血管功能障碍的潜力:本研究评估了秋水仙碱对预防缺血性中风(IS)和心房颤动(AF)患者复发中风的影响:方法: 在戈勒斯坦医院(伊朗阿瓦士)进行了一项为期一年的随机、双盲、安慰剂对照试验,研究对象为缺血性中风(IS)合并心房颤动患者。试验收集了参与者的人口统计学和临床数据,然后将他们分配到干预组或安慰剂组。实验组服用秋水仙碱,剂量为 0.05 毫克,每天两次,为期一年;对照组在相同时间内服用剂量相当的安慰剂:一年中,108 名患者完成了研究。干预组有 55 名患者,安慰剂组有 53 名患者。在试验的后三个月中,秋水仙碱组有 3 名患者、安慰剂组有 10 名患者出现中风复发。胃肠道问题是最常见的并发症(33 例),其次是肌痛(8 例)。干预后,秋水仙碱组和安慰剂组的中风复发频率和血清 C 反应蛋白(CRP)水平存在明显差异(P < 0.05):结论:在本研究中,与对照组相比,秋水仙碱能有效降低房颤 IS 患者的卒中复发率和 CRP 水平。建议进一步开展样本量更大、持续时间更长的随机对照试验,以验证本试验的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effect of Colchicine for Prevention of Recurrent Stroke in Ischemic Stroke Patients with Atrial Fibrillation: A Randomized Double-blinded Placebo-- controlled Trial.

Background: It has been proposed that colchicine may have the potential to prevent cardiovascular and cerebrovascular dysfunctions.

Objective: This study evaluated the impact of colchicine on preventing recurrent stroke in patients with both ischemic stroke (IS) and atrial fibrillation (AF).

Methods: A randomized, double-blinded, placebo-controlled trial was conducted at Golestan Hospital (Ahvaz, Iran) over one year, involving IS patients with AF. Demographic and clinical data were collected from the participants, who were then assigned to either the intervention or placebo groups. The experimental group was administered colchicine at a dosage of 0.05 mg twice daily for one year, while the control group received a placebo at a comparable dosage over the same timeframe.

Results: In one year, 108 patients completed the study. There were 55 patients in the intervention group and 53 patients in the placebo group. During the second trimester of the trial, three patients in the colchicine group and 10 patients in the placebo group experienced recurrent strokes. Gastrointestinal issues were the most commonly reported complications (33 cases), followed by myalgia (8 patients). There were significant differences in the frequency of recurrent stroke and serum levels of C-reactive protein (CRP) between the colchicine and placebo groups (P < 0.05) after intervention.

Conclusion: In this study, colchicine was effective in reducing recurrent stroke and CRP levels in IS patients with AF compared to the control group. Further randomized controlled trials with larger sample sizes and extended durations are recommended to validate the results of this trial.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Reviews on recent clinical trials
Reviews on recent clinical trials PHARMACOLOGY & PHARMACY-
CiteScore
3.10
自引率
5.30%
发文量
44
期刊介绍: Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal"s aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I – IV clinical trial studies, clinical investigations at all stages of development and therapeutics. The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信